Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

EntreMed Opens China Office

publication date: Mar 7, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
EntreMed, a Washington DC area biotech, has reacquired the China rights to its leading cancer drug candidate, ENMD-2076, and the company will open a China office to direct its work necessary for SFDA approval of the molecule. In 2010, EntreMed gave Selected Value Therapeutics a 16-month option on the China rights to ENMD-2076 as part of a $5.1 million funding. Now, following a $10 million capital raise from investors with China roots and the expiration of the prior deal, EntreMed is moving ahead on its own. More details....

Stock Symbol: (NSDQ: ENMD)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors